| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Not applicable. Bis(2-butoxyethyl) 2-hydroxyethyl phosphate is an industrial flame retardant and plasticizer and has no specific biological target for therapeutic purposes. As a trialkyl phosphate ester, it does not have a defined mechanism of action for receptor binding or enzyme inhibition relevant to pharmacology. In toxicological research, it is studied as an environmental contaminant and may be considered a suspect endocrine disruptor with potential weak anti-androgenic effects, though this is not well characterized. Its primary use remains as an additive to reduce flammability.
|
|---|---|
| ln Vitro |
In vitro, this compound is not used for biological activity or drug discovery. It is a chemical standard for analytical method development. For environmental monitoring, it is spiked into matrices such as wastewater or soil extracts at 0.1-50 ug/mL to validate extraction recovery and establish calibration curves for GC-MS or HPLC. It does not have cellular or enzymatic activities, such as inhibiting cytochrome P450 enzymes or binding to nuclear receptors in typical drug screening assays. Its main "activity" is its ability to act as a flame retardant by forming a char layer.
|
| ln Vivo |
In vivo, this compound is not a therapeutic agent and is not used in standard animal efficacy studies. It is used in non-clinical research to study the metabolism, persistence, and bioaccumulation of flame retardants. In a rodent toxicology study, the compound may be administered to assess its effects on liver function, thyroid hormone levels, or reproductive parameters. These are safety/tolerance studies rather than disease-model efficacy studies. It is also applied to plastics or textiles to test fire-retardant properties in a burn test.
|
| Enzyme Assay |
General protocol for in vitro analytical use: Prepare a 1 mg/mL stock solution in n-hexane or ethyl acetate. Prepare calibration standards in n-hexane at 0.1, 0.5, 1, 5, 10, 50, 100 ug/mL. Add 10 uL of an internal standard (e.g., tributyl phosphate-d27, 10 ug/mL) per mL of standard. Inject 1 uL into a GC-MS system with a DB-5MS column (30 m × 0.25 mm). Oven program: 60degC for 1 min, ramp 20degC/min to 300degC, hold 5 min. Quantify using SIM ions m/z 125 and 167. For water samples, extract 100 mL with 10 mL dichloromethane, dry over sodium sulfate, evaporate, and reconstitute. Store the standard at 4degC.
|
| Cell Assay |
General protocol for in vitro cell-based experiments: For an androgen receptor antagonism screening assay, culture MDA-kb2 cells in RPMI-1640 with 10% charcoal-stripped FBS. Seed in 96-well plates (1×10^4 cells/well). Treat with the compound (1-100 uM) and 1 nM DHT for 24 h. Measure luciferase activity. The compound may cause a slight inhibition at 100 uM. Perform a parallel MTT assay to confirm no cytotoxicity. This assay is for toxicological hazard identification, not drug efficacy.
|
| Animal Protocol |
General protocol for in vivo animal experiments: For a toxicokinetic study, administer the compound (100 mg/kg, oral) in corn oil to male Sprague-Dawley rats (n=5). Collect blood at 0, 1, 2, 4, 8, 12, 24, 48 h. Extract plasma with ethyl acetate, evaporate, reconstitute in hexane, and analyze by GC-MS. The half-life is expected to be 6-12 hours. This study assesses systemic exposure, not therapeutic efficacy.
|
| ADME/Pharmacokinetics |
General pharmacokinetic properties: This compound (MW 342.37) is moderately lipophilic (LogP ~2-3). It is not highly water-soluble but is soluble in organic solvents. If absorbed, it is likely rapidly metabolized by CYP450 enzymes via dealkylation, yielding dialkyl phosphates that are excreted in urine. The elimination half-life is expected to be a few hours. For storage, it is a colorless to pale yellow viscous liquid or solid, kept at 4degC. Stock solutions in hexane are stable at -20degC for 6 months.
|
| Toxicity/Toxicokinetics |
General toxicity profile: This industrial chemical is a potential irritant. It may cause skin and eye irritation upon direct contact. It is toxic to aquatic life with long-lasting effects. In a 28-day oral toxicity study in rodents, the liver is the primary target organ, with a NOAEL of approximately 100 mg/kg/day. At higher doses, hepatomegaly and increased CYP2B activity can occur. GHS hazard statements may include H315, H319, and H411. Standard safety precautions (gloves, goggles, lab coat, fume hood) should be used.
|
| Additional Infomation |
Bis(2-butoxyethyl) 2-hydroxyethyl phosphate is a trialkyl phosphate ester flame retardant and plasticizer. Its molecular formula is C14H31O7P, and it is a research-grade chemical used as a reference standard for analytical method validation and quality control. The product is strictly for laboratory research, analytical, and forensic use only, not for human or veterinary consumption. Its application is primarily in environmental chemistry to track the persistence of flame retardants in ecosystems.
|
| Molecular Formula |
C14H31O7P
|
|---|---|
| Molecular Weight |
342.37
|
| Exact Mass |
342.181
|
| CAS # |
1477494-86-2
|
| Related CAS # |
Bis(2-butoxyethyl) 2-hydroxyethyl phosphate-d4; 2469195-92-2
|
| PubChem CID |
132967161
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
22
|
| Complexity |
256
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCOCCOP(=O)(OCCO)OCCOCCCC
|
| InChi Key |
UQSRKBXTCXVEJL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H31O7P/c1-3-5-8-17-11-13-20-22(16,19-10-7-15)21-14-12-18-9-6-4-2/h15H,3-14H2,1-2H3
|
| Chemical Name |
bis(2-butoxyethyl) 2-hydroxyethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9208 mL | 14.6041 mL | 29.2082 mL | |
| 5 mM | 0.5842 mL | 2.9208 mL | 5.8416 mL | |
| 10 mM | 0.2921 mL | 1.4604 mL | 2.9208 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
